US & UK reach historic pharma pricing pact
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The antibody was designed and developed at Abzena’s Cambridge, UK,
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Subscribe To Our Newsletter & Stay Updated